Raymond James Financial’s Iovance Biotherapeutics IOVA Stock Holding History

Raymond James Financial’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.81M	Buy	436,098 +10,606	+2%	+$40.3K	﹤0.01%	3559
2026 Q1	$1.49M	Buy	425,492 +21,051	+5%	+$67.3K	﹤0.01%	3570
2025 Q4	$1.1M	Buy	404,441 +68,285	+20%	+$158K	﹤0.01%	3710
2025 Q3	$729K	Buy	336,156 +12,058	+4%	+$28.5K	﹤0.01%	3880
2025 Q2	$557K	Buy	324,098 +4,618	+1%	+$11.5K	﹤0.01%	3950
2025 Q1	$1.06M	Sell	319,480 -1,243,816	-80%	-$6.41M	﹤0.01%	3441
2024 Q4	$11.6M	Buy	+1,563,296	New	+$14.5M	﹤0.01%	1731

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Raymond James Financial's IOVA Position: Q2 2026 in Review

Raymond James Financial increased its Iovance Biotherapeutics (IOVA) stake by 2.5% in Q2 2026, buying an estimated $40.3K and bringing the position to 436,098 shares worth $1.81M. The position accounts for ﹤0.01% of the portfolio, ranked #3559.

Raymond James Financial first reported a position in IOVA in Q4 2024 and has held it in 7 quarters since. The position peaked at $11.6M in Q4 2024. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Raymond James Financial held 436,098 shares of Iovance Biotherapeutics worth $1.81M as of Q2 2026.
Raymond James Financial bought 10,606 Iovance Biotherapeutics shares in Q2 2026, an estimated $40.3K.
Iovance Biotherapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #3559 holding.
Raymond James Financial first reported a position in Iovance Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
Raymond James Financial's Iovance Biotherapeutics position peaked at $11.6M in Q4 2024.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.